Core Viewpoint - Hualan Co., Ltd. is expanding its strategic footprint in the AI-driven drug development sector through a capital increase agreement with several biotech firms, indicating a commitment to align with national strategies and enhance its technological capabilities in this emerging field [1] Group 1: Investment Details - Hualan's wholly-owned subsidiary, Lingqing Zhizhi, has signed a capital increase agreement with Shenzhen Jingtai and other companies to invest in Kema Biotechnology [1] - Lingqing Zhizhi plans to use its own funds of 20 million yuan to subscribe to the newly increased registered capital of Kema Biotechnology, acquiring a 9.53% stake on a fully diluted basis [1] - Following the agreement, Lingqing Zhizhi will secure a board seat at Kema Biotechnology and gain a preferential right to acquire shares under the same conditions [1] Group 2: Company Background - Kema Biotechnology, established in 2021, focuses on antibody design using generative AI models and is incubated by the leading AI innovative drug development company, Jingtai Holdings [1] Group 3: Strategic Implications - This investment marks a significant step for Hualan Co., Ltd. in responding to national strategies and solidifying its presence in the AI innovative drug development sector [1] - The company aims to deepen its engagement in AI drug research and development by attracting top industry experts and building a diversified business team to enhance its technical service capabilities [1]
华兰股份子公司拟以2000万元增资科迈生物